| By Marketwire . |
Article Rating: |
|
| November 9, 2012 02:41 AM EST |
Reads: |
267 |
LUND, SWEDEN -- (Marketwire) -- 11/09/12 --
· Laquinimod - Teva to initiate a new Phase III study in the US at
year-end
- milestone payment of USD 5 M received following a
submitted
application for regulatory approval in Europe
- Crohn's Phase II data presented at the UEGW conference
· TASQ - biomarker data presented at the ESMO conference
- Ipsen to initiate two new clinical Phase II studies:
maintenance therapy for prostate cancer and a study of other types of
cancer
· ANYARA - Phase III study results to be presented Q1 2013
· 57-57 - clinical trial of systemic sclerosis/scleroderma is
in progress
· ISI - project proceeding as planned
· Net sales: SEK 136.4 M (231.3)
· Operating loss: SEK 168.7 M (loss 6.2)
· Loss after tax: SEK 175.1 M (loss: 1.3)
· Loss per share for the period: SEK 2.54 (loss: 0.02)
This report is also available at www.activebiotech.com
Active Biotech AB Interim report January - September 2012:
http://hugin.info/1002/R/1656396/535516.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1656396]
